Subscribe To
Zoetis: significant capex investments for long-term growth, but a hold now
Zoetis is an animal health company specializing in the development and manufacturing of veterinary pharmaceuticals and vaccines for both livestock and...
October 26, 2023, 1:18 am
Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...
October 25, 2023, 9:05 am
Comera life sciences presents sqore™ platform technology data at podd: partnerships in drug delivery conference
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generat...
October 16, 2023, 12:00 pm
New rsv protections for infants hit cost, insurance hurdles in u.s. rollout
Pfizer's maternal vaccine, Abrysvo, and Sanofi's monoclonal antibody, Beyfortus, were approved for expe...
October 13, 2023, 12:22 pm
Astria therapeutics strikes exclusive license agreement for dermatitis treatment portfolio
Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of ...
October 12, 2023, 9:33 am
Tiziana life sciences to present ms treatment at ectrims annual congress
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that a late breaking poster titled, "Treatment Of Six Non-Active Secondary Progressive MS With N...
October 11, 2023, 9:26 am
Acumen pharmaceuticals: novel alzheimer's molecule with positive early data
Acumen Pharmaceuticals is developing a monoclonal antibody, ACU193, that targets Amyloid beta oligomers...
October 3, 2023, 5:15 am
Eli lilly gets fda complete response letter for skin treatment after inspection of third-party facility
Eli Lilly & Co. said Monday the U.S. Food and Drug Administration has issued a complete response letter for its lebrikizumab, a treatment for moderate...
October 2, 2023, 6:59 am
Leqembi® intravenous infusion (lecanemab) approved for the treatment of alzheimer’s disease in japan
TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (...
September 25, 2023, 5:02 am
Vigil neuroscience: interesting early data, wait for phase 2
Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial function. Their lead candidate, VGL101, is a ...
September 18, 2023, 2:38 pm
Regeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts say
Regeneron Pharmaceuticals Inc.'s REGN, +0.74% agreement with the federal government to limit the list price of any new COVID ...
September 15, 2023, 8:40 am
Sensei biotherapeutics to present new preclinical data supporting mechanism of action, pharmacokinetic profile and safety characteristics for sns-101, a conditionally active vista-blocking antibody, a
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the disco...
September 13, 2023, 11:30 am
Alector (alec) up 7% on finishing enrolment in alzheimer study
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antib...
September 8, 2023, 1:32 pm
Tiziana life sciences highlights publication of promising intranasal foralumab in alzheimer's study results
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said a study validating the mechanism of action of its drug candidate intranasal foralumab in Alzheimer's Dise...
September 6, 2023, 9:33 am
Invivyd (ivvd) stock rises 18% in 3 months: here's why
Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its ...
August 29, 2023, 2:17 pm
Regeneron gets federal funding for next-generation covid treatment
Regeneron Pharmaceuticals Inc. REGN, -0.32% said Tuesday that the Biomedical Advanced Research and Development Authority has agreed to support the dev...
August 22, 2023, 2:34 pm
Comera life sciences announces publication of study reinforcing caffeine’s viscosity reducing capabilities
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formul...
August 16, 2023, 12:00 pm
Macrogenics announces date of second quarter 2023 financial results conference call
ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing an...
July 31, 2023, 5:35 pm
Eli lilly to acquire versanis bio, expanding obesity-treatment pipeline
Eli Lilly and Co. LLY, -1.34% will acquire Versanis Bio, a private clinical-stage biopharma company focused on new treatments for cardiometabolic dise...
July 14, 2023, 8:14 am
Aslan pharmaceuticals shares slide amid new data on atopic dermatitis treatment
Shares of Aslan Pharmaceuticals ASLN were down 32% premarket on Thursday after the company released new data from a clinical study of eblasakimab, an ...
July 6, 2023, 8:22 am